Tech Company Financing Transactions

Affinia Therapeutics Funding Round

On 5/4/2021, Affinia Therapeutics raised $110 million in Series B investment from EcoR1 Capital Management, Farallon Capital Management and Atlas Venture.

Transaction Overview

Company Name
Affinia Therapeutics
Announced On
5/4/2021
Transaction Type
Venture Equity
Amount
$110,000,000
Round
Series B
Investors

EcoR1 Capital Management (Lead Investor) (Caroline Stout)

Farallon Capital Management (Lead Investor)

Atlas Venture (David Grayzel)

Avidity Partners

Casdin Capital

F-Prime Capital (Robert Weisskoff)

GV

Lonza Group AG

Mass General Brigham Innovation

New Enterprise Associates (Ed Mathers)

Octagon Investments Fund

Perceptive Advisors

RA Capital

TCG Crossover

Woodline Partners

Proceeds Purpose
Affinia Therapeutics will use the proceeds of the Series B financing to further develop its proprietary gene therapy platform, advance programs into the clinic, and for general corporate purposes.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
43 Foundry Ave. 120
Waltham, MA 02453
USA
Phone
(617) 430-7817
Website
www.affiniatx.com
Email Address
[email protected]
Overview
At Affinia Therapeutics, our purpose is to develop gene therapies that can have a transformative impact on people affected by devastating genetic diseases. Our proprietary platform enables us to methodically engineer novel AAV vectors and gene therapies that have remarkable tissue targeting and other properties.
Profile
Affinia Therapeutics LinkedIn Company Profile
Social Media
Affinia Therapeutics Company Twitter Account
Company News
Affinia Therapeutics News
Facebook
Affinia Therapeutics on Facebook
YouTube
Affinia Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Rick Modi
  Rick Modi LinkedIn Profile  Rick Modi Twitter Account  Rick Modi News  Rick Modi on Facebook
Chief Medical Officer
Petra Kaufmann
  Petra Kaufmann LinkedIn Profile  Petra Kaufmann Twitter Account  Petra Kaufmann News  Petra Kaufmann on Facebook
Chief Scientific Officer
Charles Albright
  Charles Albright LinkedIn Profile  Charles Albright Twitter Account  Charles Albright News  Charles Albright on Facebook
Chief Technical Officer
Robert May
  Robert May LinkedIn Profile  Robert May Twitter Account  Robert May News  Robert May on Facebook
Co-Founder
Botond Roska
  Botond Roska LinkedIn Profile  Botond Roska Twitter Account  Botond Roska News  Botond Roska on Facebook
Co-Founder
Aaron Tward
  Aaron Tward LinkedIn Profile  Aaron Tward Twitter Account  Aaron Tward News  Aaron Tward on Facebook
Co-Founder
Luk Vandenberghe
  Luk Vandenberghe LinkedIn Profile  Luk Vandenberghe Twitter Account  Luk Vandenberghe News  Luk Vandenberghe on Facebook
VP - Bus. Development
Paula Cobb
  Paula Cobb LinkedIn Profile  Paula Cobb Twitter Account  Paula Cobb News  Paula Cobb on Facebook
VP - Bus. Development
Laura Richman
  Laura Richman LinkedIn Profile  Laura Richman Twitter Account  Laura Richman News  Laura Richman on Facebook
VP - General Counsel
Robert Aboud
  Robert Aboud LinkedIn Profile  Robert Aboud Twitter Account  Robert Aboud News  Robert Aboud on Facebook

 

 

Browse more venture capital transactions:

Prev: 5/4/2021: RazorMetrics venture capital transaction
Next: 5/4/2021: Movia Robotics venture capital transaction

 

Share this article

 

About Database of VC Transactions

Our team works diligently to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.